9-28 | Governments must now turn words on paper into practice and take the necessary steps to save more lives of people with TB.
9-19 | Ahead of the global tuberculosis High-Level Meeting at the United Nations, MSF calls on Johnson & Johnson not to enforce any secondary patents for bedaquiline in any country with a high burden of TB.We also call on Cepheid to drop the price of the GeneXpert TB test from US$10 to US$5 in order to save lives.
8-8 | Since March 2022, an MSF – Hong Kong team with doctors, nurses, psychologists, and engineers, has conducted multi-disciplinary assessments in 16 elderly homes and residential care homes for persons with disabilities to cope with potential future outbreaks. The team has provided key recommendations on ventilation and air quality, infection and prevention control, as well as mental health and emotional well-being of the residents and staff.
5-17 | Médecins Sans Frontières/Doctors Without Borders (MSF) are pleased that, having shared the results of TB-PRACTECAL, our clinical trial that found a new, safer and more effective six-month oral treatment regimen for multi drug-resistant tuberculosis (MDR-TB), the World Health Organization (WHO) have announced it will update global guidance on treatment. Following the results of MSF’s trial the WHO are now recommending programmatic use of the 6- month BPaLM regimen – comprising bedaquiline, pretomanid, linezolid (600 mg) and moxifloxacin in MDR-TB patients in pla
5-4 | The COVID-19 vaccine Humanitarian Buffer (HB) is failing its mission to support people hit by the pandemic and struggling to access immunisation, says Médecins Sans Frontières (MSF). The HB is part of the COVAX mechanism*, whose aim is to assist groups of people who do not have access to COVID-19 vaccination in situations of humanitarian emergency. However, MSF’s recent experience in northern Syria has highlighted the system’s limitations and ultimate failure to fulfil its purpose.